NASDAQ:PDLI

PDL BioPharma (PDLI) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.47
$2.47
50-Day Range
$2.47
$2.47
52-Week Range
$2.09
$3.86
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PDLI stock logo

About PDL BioPharma Stock (NASDAQ:PDLI)

PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

PDLI Stock News Headlines

GT Biopharma Inc GTBP
Health Winners & Losers: Maxygen
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
PDLI Historical Data
ABVC - ABVC BioPharma, Inc.
RDHL - RedHill Biopharma Ltd.
LABP
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Steris (STE)
See More Headlines
Receive PDLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2020
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PDLI
CUSIP
69329Y10
Employees
109
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Dominique P. Monnet (Age 59)
    CEO, Pres & Director
    Comp: $1.2M
  • Mr. Edward A. Imbrogno CPA (Age 55)
    VP, CFO & Chief Accounting Officer
    Comp: $564.14k
  • Mr. Christopher L. Stone (Age 56)
    VP, Gen. Counsel & Sec.
    Comp: $1.15M
  • Mr. Nathan Kryszak
    Deputy Gen. Counsel & Assistant Sec.

PDLI Stock Analysis - Frequently Asked Questions

How were PDL BioPharma's earnings last quarter?

PDL BioPharma, Inc. (NASDAQ:PDLI) announced its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter.

What other stocks do shareholders of PDL BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Bausch Health Companies (BHC) and Cara Therapeutics (CARA).

This page (NASDAQ:PDLI) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners